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Short running title:  Periconceptional glucosamine and pregnancy outcome 
 
Abstract 1 
Exposure of cumulus-oocyte complexes to the hyperglycaemia mimetic, glucosamine 2 
during in vitro maturation impairs embryo development, potentially through up-regulation 3 
of the hexosamine biosynthesis pathway.  This study examined the effects of in vivo 4 
periconception glucosamine exposure on reproductive outcomes in young healthy mice, 5 
and further assessed the effects in overweight, high fat-fed mice. Eight week old mice 6 
received daily glucosamine injections (20 or 400 mg/kg) for 3-6 days before and 1 day 7 
after mating (periconception). Outcomes were assessed at day 18 gestation. 8 
Glucosamine treatment reduced litter size, independent of dose. A high fat diet (21% fat) 9 
for 11 weeks prior to and during pregnancy reduced fetal size. No additional effects of 10 
periconception glucosamine (20 mg/kg) on pregnancy outcomes were observed in fat-fed 11 
mice. In mice fed control 6% fat diet glucosamine treatment at 16 weeks of age reduced 12 
fetal weight and increased congenital malformations.  As differing effects of glucosamine 13 
were observed in 8-week and 16-week old control mice, maternal age effects were 14 
assessed.  Periconception glucosamine at 8 weeks reduced litter size, while glucosamine 15 
treatment at 16 weeks reduced fetal size. Thus, in vivo periconception glucosamine 16 
exposure perturbs reproductive outcomes in mice, with the nature of the outcomes 17 
dependent upon maternal age. 18 
 19 
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The link between hyperglycaemia and adverse reproductive outcomes has been 23 
extensively and well documented (Miller et al. 1981; Combs and Kitzmiller, 1991; Greene, 24 
1999; McCance 2011; Simmons, 2011).  Despite recent advances in therapeutic 25 
management there are still markedly greater rates of complications in pregnancies 26 
accompanied by hyperglycaemia, rather than normoglycaemia (Metzger et al. 2007; 27 
Kitzmiller et al. 2008; Shand et al. 2008; Ali and Dornhorst, 2011).  The periconception 28 
period has recently emerged as a period of acute sensitivity to changes in the maternal 29 
metabolic environment. Negative effects of periconceptional maternal hyperglycaemia, 30 
diabetes and obesity on the developing oocyte and preimplantation embryo have been 31 
described, with consequences for pregnancy success, fetal development and postnatal 32 
outcomes (Jungheim and Moley 2008; Minge et al. 2008; Wyman et al. 2008; Jungheim 33 
2010; Ramin et al 2010; Wang and Moley 2010; Cardozo et al. 2011; Fleming et al. 34 
2012). 35 
 36 
Glucosamine (GlcN), the simple amino sugar, has been documented to upregulate the 37 
hexosamine biosynthesis pathway, as it is converted to GlcN-6-phosphate, an 38 
intermediate of the pathway that bypasses the rate limiting glutamine-fructose-6-39 
phosphate amidotransferase enzyme (GFAT) (Marshall et al. 1991; McClain and Crook, 40 
1996).  In somatic tissues, elevated flux through the hexosamine pathway has been 41 
associated with perturbed health states, including insulin resistance (Marshall et al. 1991; 42 
Patti et al. 1999; McClain 2002; Buse 2006; Teo et al. 2010).  Previous studies have 43 
demonstrated that exposure of murine, bovine and porcine cumulus-oocyte complexes 44 
(COCs) to GlcN during in vitro maturation significantly reduces subsequent embryo 45 
developmental competence (Sutton-McDowall et al. 2006; Kimura et al. 2008; Schelbach 46 
et al. 2010).  Similarly, GlcN addition during murine embryo culture impairs blastocyst 47 
development (Pantaleon et al. 2010), while addition of GlcN to bovine embryo culture, 48 
from the 8-cell stage, decreases the development rate of embryos and skews the sex 49 
ratio towards males (Kimura et al. 2008). During maturation of the COC, significant 50 
glucose flux through the hexosamine biosynthesis pathway supports expansion of the 51 
cumulus matrix (Sutton-McDowall et al. 2004), as UDP-N-acetyl glucosamine, the end 52 
product of the pathway, is the substrate for hyaluronic acid synthesis.  However, UDP-53 
acetyl glucosamine also serves as the substrate for O-linked glycosylation of serine and 54 
threonine residues in a range of proteins (Torres and Hart 1984). Hyperglycaemic 55 
disruption of cellular function is thought to be mediated through increased levels of O-56 
linked glycosylation and altered function of key proteins as a result of upregulated 57 
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hexosamine biosynthesis pathway activity (Vosseller et al. 2002; Love and Hanover 2005; 58 
Butkinaree et al. 2010).  Similarly, in vitro studies support a role for up regulation of the 59 
hexosamine biosynthesis pathway and perturbed O-linked glycosylation in mediating the 60 
negative effects of exposing COCs or early embryos to GlcN (McDowell et al. 2006; 61 
Pantaleon et al. 2010; Schelbach et al. 2010). 62 
 63 
While the effects of in vitro exposure of developing oocytes and embryos to GlcN have 64 
been assessed, and studies have begun to investigate the mechanisms underlying these 65 
outcomes (McDowell et al. 2006; Pantaleon et al. 2010; Schelbach et al. 2010), the 66 
potential for in vivo effects of GlcN on oocyte and early embryonic development has been 67 
little considered.  One small study of 54 women who used GlcN during pregnancy 68 
reported no adverse fetal effects (Sivojelezova et al. 2007).  In mice, administration of 69 
GlcN at day 7.5 gestation has been shown to increase the incidence of neural tube 70 
defects (Horal et al. 2004), demonstrating that postimplantation exposure to GlcN can 71 
have negative effects in rodents. We therefore conducted studies to determine whether 72 
GlcN administration during the periconception period would affect reproductive outcomes 73 
in mice.  Additional studies further assessed these effects in mice maintained on a high 74 
fat diet, to determine whether GlcN effects would be exacerbated in conditions of 75 
perturbed maternal metabolic state. These studies suggested the potential for the effects 76 
of GlcN on reproductive outcomes to be influenced by maternal age, therefore, the effects 77 
of periconception GlcN in mice of differing ages were also assessed. 78 
 79 
Methods and Materials 80 
Unless otherwise stated all chemicals were purchased from Sigma Chemical Co. (St 81 
Louis, USA). 82 
Animals 83 
Male and female C57Bl/6 mice were obtained from Laboratory Animal Services at The 84 
University of Adelaide. Mice were housed in the animal facilities at The Queen Elizabeth 85 
Hospital, Woodville, South Australia for Experiment 1 and at The University of Adelaide 86 
Medical School, Adelaide, South Australia, for Experiments 2 and 3.  Mice were kept 87 
under 14:00-10:00 light-dark conditions and all females were first parity.  Experiments 88 
were approved by the Animal Ethics Committees of Queen Elizabeth Hospital and The 89 
University of Adelaide. 90 
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Experiment 1:  The effects of periconception GlcN treatment on pregnancy outcomes.  91 
GlcN treatment 92 
Seven week-old naturally cycling female mice were weighed and divided into three, 93 
weight-matched groups.  One week later, groups were randomly allocated to receive 94 
either 0, 20 or 400 mg/kg GlcN per day (for an association, 20 mg/kg equates to a daily 95 
dose of approximately 1500 mg in adult humans).  Eight replicate experiments were 96 
performed with 3 mice per treatment group (total of 24 per treatment).  Mice were 97 
weighed, and injected intraperitoneally with 5 l per gram body weight of Dulbecco’s PBS 98 
(0 mg/kg GlcN), or a solution of 4 mg/ml GlcN in PBS (20 mg/kg GlcN) or a solution of 80 99 
mg/ml GlcN in PBS (400 mg/kg GlcN).  Mice were injected for 3 consecutive days.  All 100 
injections throughout the study were administered at 24 hour intervals. On the third day, 101 
each female was housed overnight with a male, and mating success was determined via 102 
the detection of a vaginal sperm plug the next morning.  All mice were again treated with 103 
glucosamine or PBS on the fourth day.  For successfully mated females this was the final 104 
injection. Females that did not mate were re-introduced to males and daily injections 105 
repeated until mating was achieved (followed by a final injection on the day following 106 
successful mating), or until mating had been attempted for a maximum of 4 nights, with 107 
those that did not mate excluded from the study.  Therefore, females received between 4-108 
7 glucosamine or PBS injections.  Males were randomly allocated to females from 109 
different treatment groups throughout all replicates.  110 
Pregnancy outcomes  111 
On day 18 of pregnancy, mice were killed by cervical dislocation and post-mortem 112 
examinations were performed. The number of pregnant mice was recorded.  Total fetuses 113 
and fetal resorptions were counted in each uterine horn. Litter size was defined as the 114 
total number of viable fetuses.  Each fetus and its corresponding placenta were isolated, 115 
weighed, briefly examined for gross morphological appearance and classified as either 116 
normal or abnormal.  Fetal crown-rump length was recorded. 117 
Experiment 2: Periconception GlcN treatment in mice maintained on different fat content 118 
diets – effects on pregnancy outcomes. 119 
Dietary manipulation 120 
Five-week-old female C57Bl/6 mice were weighed and randomly allocated into two 121 
groups, which were maintained on either a low fat (LF) ((w/w) 6% fat (SF04–057)) or high 122 
fat, high cholesterol diet (HF) ((w/w) 21% fat, 0.15% cholesterol (SF00–219)) diet 123 
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(Specialty Feeds, Glen Forrest, Australia) (Table 1). Twelve mice were allocated per 124 
treatment group and eight replicate experiments were performed (total of 96 mice per 125 
dietary group). Mouse weights were recorded weekly. 126 
Plasma insulin and glucose tolerance 127 
Blood samples were collected following 7, 10 and 11 weeks of dietary manipulation.  Mice 128 
were fasted overnight and 400 – 600 µl blood was collected from anaesthetised mice via 129 
an orbital bleed.  Blood was centrifuged for 10 min at 4oC, and plasma was collected and 130 
stored at -20˚C.  Plasma insulin levels were measured in duplicate using a Rat Insulin RIA 131 
Kit (LINCO Research, Inc., St. Charles, MO, USA), with a sensitivity of 0.1 ng/ml and an 132 
intra-assay coefficient of 1.4 – 4.6 %. Samples were collected from six mice per dietary 133 
group from two replicates, giving a total of 12 mice per dietary group.   134 
Following blood collection at 10 weeks of dietary intervention, mice were allowed to 135 
recover from the anaesthesia for one hour.  An intraperitoneal glucose tolerance test was 136 
then performed.  Mice were injected intraperitoneally with 1 g D-glucose/kg bodyweight. 137 
Blood samples were collected by nicking of the tail vein, and blood glucose was 138 
measured using an Accu-Check® Advantage Glucometer at 0, 15, 30, 60, 90 and 120 139 
minutes post-glucose injection. Glucose tolerance was assessed by calculating area 140 
under the glucose curve (Le Floch et al. 1990). 141 
GlcN treatment  142 
Following 11 weeks of dietary manipulation, mice were weighed and randomly assigned 143 
to receive either 0 or 20 mg/kg GlcN.  This resulted in four treatment groups 1) LF – GlcN, 144 
2) LF + GlcN, 3) HF – GlcN and 4) HF + GlcN with 48 mice per group.  The average 145 
weight of all mice that had been on the low fat diet was used to determine the volume of a 146 
4 mg/kg GlcN solution to correspond to a 20 mg/kg dose (i.e. 5 l per kg bodyweight). 147 
This standardized volume was administered to all GlcN-treated mice in the LF and HF 148 
dietary groups, to avoid significant variation in total dosage due to different body weights.  149 
An equivalent volume of PBS was administered to control animals in LF and HF groups.  150 
Mice were injected with GlcN as described in Experiment 1, with the exception that 151 
females were placed with males for a maximum of 2 nights. Hence, mice in Experiment 2 152 
were treated for 4-5 days with GlcN. Mice were maintained on their assigned LF or HF 153 
diets throughout pregnancy. 154 
To determine whether GlcN treatment influenced glucose tolerance, mice that did not 155 
mate after two attempts were fasted overnight on the day of the final (fifth) GlcN injection.  156 
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Fasting blood samples were collected and glucose tolerance tests were performed as 157 
described above.  158 
Pregnancy outcomes 159 
Fetal and placental outcomes were assessed according to the methods described for 160 
Experiment 1.  In addition, placental length and width were recorded to determine 161 
placental volume.  Ovaries were also removed and corpora lutea (CL) numbers were 162 
counted as an indication of ovulation rate. 163 
Experiment 3: Periconception GlcN treatment of 8 and 16 week old mice – effects on 164 
pregnancy outcomes. 165 
GlcN treatment  166 
Based on an observation of different effects of GlcN treatment in mice fed the control 167 
mouse chow diet in Experiments 1 and 2, the effects of maternal age at GlcN 168 
administration on reproductive outcomes were assessed.  Five week old (young) and 13 169 
week old (adult) mice were weighed weekly for 3 weeks.  At 8 and 16 weeks of age, each 170 
age group was divided into weight-matched subgroups to receive either 0 or 20 mg/kg 171 
GlcN.  This created 4 groups (8 wks - GlcN, 8 wks + GlcN, 16 wks - GlcN, and 16 wks + 172 
GlcN).   Three mice were allocated to each treatment group, and eight replicates were 173 
performed (total of 24 mice per treatment group).  174 
For each replicate, average weights for the 8 week old and 16 week old mice were used 175 
to calculate the volume of 4 mg/kg GlcN solution to correspond to a 20 mg/kg dose for 176 
each age group (as per Experiments 1 and 2). An equivalent volume of PBS was 177 
administered to control animals (0 mg/kg GlcN) in each of the age groups.  Mice received 178 
injections of PBS or GlcN for a minimum of 4 and a maximum of 7 days as described in 179 
Experiment 1.  Pregnancy outcomes were assessed at day 18 gestation as described for 180 
Experiment 2. 181 
Statistics 182 
Statistical analysis was performed with SAS (Statistical Analysis Software) version 9.2. 183 
Chi–squared analyses were performed for parameters relating to mating (n, %), 184 
pregnancy (n, %), viable day 18 fetuses (%), resorptions from implantations (%), fetuses 185 
with abnormalities (n, %) and pregnancies with abnormal fetuses (n, %).  Comparison of 186 
the mean weekly weight change in mothers across all replicates for both experimental 187 
groups was performed with a Repeated Measures ANOVA and Bonferroni corrected 188 
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pairwise comparison. Parameters relating to fetal and placental size, litter size, 189 
implantation number and resorption number were assessed with a One-way ANOVA in 190 
Experiment 1 and a Two-way ANOVA in Experiments 2 and 3 using a mixed model 191 
analysis.  In Experiments 2 and 3, CL number was also analysed via Two-way ANOVA.  192 
In addition, serum insulin levels and area under the curve was assessed by Two-way 193 
ANOVA.  Bonferroni post hoc tests were performed for all ANOVAs. All mixed model 194 
analyses were performed both with and without the inclusion of co-variates, including 195 
days of GlcN exposure, maternal weight at pregnancy, litter size, implantation number 196 
and resorption number. Any effects of covariates on outcomes are reported and unless 197 
otherwise stated, reported statistics are unadjusted for covariates.  198 




Experiment 1:  The effects of periconception GlcN on pregnancy outcomes.  201 
Pregnancy rates 202 
GlcN treatment did not affect the number or proportion of mice that mated, as indicated by 203 
the presence of a sperm plug.  Similarly, there were no differences between treatment 204 
groups in the number of mice that were pregnant on day 18, or the proportion of mice that 205 
were pregnant relative to those that successfully mated (Table 2).   206 
Litter size 207 
Regardless of dose administered, GlcN treatment reduced the number of implantations 208 
and litter size (number of viable fetuses) at day 18 gestation (P < 0.05).  The number of 209 
resorptions detected at day 18 pregnancy was not altered by GlcN treatment, but when 210 
expressed as a percentage of implantations, resorption rate was increased by GlcN 211 
treatment, regardless of dose (Table 2).   212 
Fetal outcomes 213 
Periconception GlcN treatment did not alter fetal weight or length of the viable fetuses at 214 
day 18 of pregnancy (Table 2) but tended to increase placental weight (P = 0.08).  Birth 215 
defects, as determined by gross morphological appearance on day 18 gestation were not 216 
associated with any treatment.  A single fetus presented with one very small eye in the 217 
control group, and another fetus had an abdominal hernia in the GlcN 20 mg/kg group.  218 
Experiment 2: Periconception GlcN treatment in mice maintained on different fat content 219 
diets.  220 
Effects of dietary manipulation on bodyweight and glucose tolerance prior to GlcN 221 
administration 222 
Female mice maintained on the HF diet were heavier than their LF counterparts from5 223 
weeks of dietary manipulation (LF diet:  21.1 ± 0.2 g (n=96); HF diet: 23.6 ± 0.3 g (n=96)) 224 
(P < 0.05).  The weight difference increased, such that mice fed the HF diet were 22% 225 
heavier than the LF fed group by the time of mating at 11 weeks of dietary exposure (LF 226 
diet:  24.8 ± 0.3 g (n=96); HF diet: 30.5 ± 0.4 g (n=96)) (P < 0.05)).    227 
After ten weeks of high fat feeding, there was no significant difference in glucose 228 
tolerance, assessed as glucose area under the curve, for mice on the LF and HF diets (LF 229 
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diet: 2402 ± 154 mM/ 120 min (N=12); HF diet: 2663 ± 124 mM/ 120 min (N=12)). There 230 
were also no differences detected in plasma insulin levels for mice maintained on the two 231 
diets at either 7 weeks (LF: 0.26 ± 0.06 ng/ml (n=10), HF: 0.23 ± 0.04 ng/ml (n=7)), 9 232 
weeks (LF: 0.22 ± 0.04 ng/ml (n=9), HF: 0.24 ± 0.04 ng/ml (n=9)) or 10 weeks (LF: 0.28 ± 233 
0.09 ng/ml (n=8), HF: 0.30 ± 0.08 ng/ml (n=9)) of dietary exposure. Insulin levels were 234 
measured in 12 mice from each dietary group at each time point, and were below the 235 
levels of detection for the assay (0.1 ng/ml) in 2-5 mice per group. 236 
Glucose tolerance following GlcN administration 237 
Glucose area under the curve in a glucose tolerance test, in non-pregnant mice, was not 238 
altered by 5 days GlcN treatment and did not differ between dietary groups (mM/ 120 min) 239 
(LF – GlcN:  2893 ± 95 (n = 10), LF + GlcN: 2807 ± 128 (n = 12), HF – GlcN: 3005 ± 112 240 
(n = 12), HF + GlcN: 3080 ± 128 (n = 12)). 241 
Pregnancy rates 242 
Mice in this experiment were placed with males for a maximum of 2 nights, resulting in 243 
lower proportions mating when compared to Experiments 1 or 3.  GlcN treatment did not 244 
affect the number or proportion of mice that mated.  However, more LF mice that were 245 
treated with GlcN became pregnant than those maintained on a LF diet and not given 246 
GlcN (P < 0.05) (Table 3).  In addition, less GlcN treated HF fed mice became pregnant 247 
after mating, when compared to GlcN treated LF fed mice, or when compared to HF fed 248 
mice that were not treated with GlcN (P < 0.05) (Table 3). 249 
Litter size 250 
Implantation number, litter size and resorption rates at day 18 of pregnancy were not 251 
affected by GlcN treatment or high fat feeding (Table 3).  Ovulation rate, as indicated by 252 
the number of corpora lutea present at day 18 gestation, was also not affected by any 253 
treatment (Table 3). 254 
Fetal outcomes 255 
Fetal weight at day 18 of pregnancy was reduced by maternal high fat feeding (P < 0.05, 256 
Table 4). Periconceptional exposure to GlcN also reduced fetal weight (P < 0.05, Table 4). 257 
Although there was no significant interaction between the two factors, fetal weight was 258 
reduced by GlcN only in LF-fed mice.  Exposure to a HF maternal diet also reduced fetal 259 
length (P < 0.05, Table 4), while periconception GlcN exposure did not affect fetal length 260 
(Table 4). Placental weight did not differ between treatment groups (Table 4).  Placental 261 
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volume tended to be reduced in mothers fed a HF diet (P = 0.08), but there were no 262 
differences in placental volume between GlcN treatment groups (Table 4). 263 
An increased number (P < 0.001) and proportion (P < 0.01) of fetuses presented with 264 
congenital abnormalities in the LF + GlcN group, when compared to all other groups 265 
(Table 4).  Similarly, the number (P < 0.01) and proportion (P < 0.001) of pregnancies 266 
containing a fetus with abnormalities was higher for the LF + GlcN group relative to all 267 
others (Table 4).  The proportion of mothers that carried birth-defected fetuses was also 268 
increased by exposure to a HF diet, irrespective of GlcN treatment, when compared to the 269 
LF – GlcN group (Table 4).  The majority of abnormalities were eye defects (LF+GlcN: 270 
n=14/17 fetuses; HF-GlcN: n=3/4 fetuses; HF+GlcN: n=2/3 fetuses), characterised by 271 
missing one or both eyes or having underdeveloped eyes.  Identification of defects was 272 
performed by gross examination only, no further histopathological analysis of the 273 
ophthalmic defects was performed. An abdominal omphalocele was present in 3 fetuses 274 
from the LF + GlcN group, and 1 fetus from each of the HF - GlcN and HF + GlcN groups.  275 
Experiment 3: Periconception GlcN treatment of 8 and 16 week old mice. 276 
Because different effects of GlcN treatment were observed in mice fed the control mouse 277 
chow diet between Experiments 1 and 2, we decided to investigate the effect of maternal 278 
age at periconceptual GlcN administration (8 wk vs. 16 wk) on reproductive outcomes, as 279 
this was the only major difference between the experimental groups.  Older mice were 280 
heavier than younger mice for the 3 weeks they were housed prior to GlcN treatment 281 
(bodyweight at mating at 8 wk: 22.1 ± 0.2 g (n=24); bodyweight at mating at 16 wk: 25.0 ± 282 
0.4 g (n=24) (P < 0.05)). 283 
Pregnancy rates 284 
GlcN treatment and maternal age did not affect the number or proportion of mice that 285 
mated or became pregnant (Table 5).  Significantly more mice mated over the first 2 days 286 
compared to the third and fourth days (data not shown, P < 0.0001).   287 
Litter size 288 
An interaction effect was detected between GlcN and maternal age for the number of 289 
implantations and litter size (P < 0.01 for both), where GlcN administration in 8 wk old 290 
mice reduced implantations and litter size, but not in 16 wk old mice (GlcN x age 291 
interaction, P < 0.01 for both) (Table 5). Implantation number tended to be reduced by 292 
GlcN in 16 wk old mice, when compared to 16 wk mice that did not receive GlcN, but this 293 
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was not significant.  Older mice that were not treated with GlcN had higher implantation 294 
rates and litter sizes than young mice (P < 0.01) (Table 5).   295 
Overall, the total number of implantations (P < 0.0001) and viable fetuses (P < 0.0001) 296 
was lowest in the 8 wk + GlcN group.  No differences in the number of resorptions were 297 
seen between the four groups (Table 5), however, a greater proportion of implantations 298 
resorbed (P < 0.05) in 8 wk old GlcN treated mice (Table 5).  Mean ovulation rate, as 299 
determined by CL number, tended to be decreased in young mice that received 20 mg/kg 300 
GlcN, although this was not significant (P = 0.076) (Table 5). 301 
Fetal outcomes 302 
Maternal age did not independently influence fetal weight whereas GlcN was found to 303 
have a significant effect on fetal weight (P < 0.05), and there was a significant interaction 304 
between GlcN and maternal age (P < 0.01).  Fetal weight was reduced by periconception 305 
GlcN treatment in 16 wk old mice (P < 0.05) (Table 6), while the same treatment did not 306 
affect fetal weight in 8 wk old mice.  307 
GlcN reduced fetal length in pups derived from 16 wk old GlcN treated mice (P < 0.05) 308 
(Table 6).  For fetal length, a significant interaction was observed between GlcN and 309 
maternal age (P < 0.04), that was lost when maternal weight was included in the analysis 310 
as a co-variate, suggesting that maternal weight may be a contributing component to age-311 
associated changes in fetal size. 312 
Placental weight was increased in 8 wk old mice treated with GlcN, when compared to all 313 
other groups (P < 0.05, Table 6).  There was no effect of maternal age on placental 314 
weight.  No differences were detected in placental volumes between the 4 groups (Table 315 
6). 316 
A significantly higher number of abnormal fetuses were present in litters of 16 wk old GlcN 317 
treated mice, compared to all other groups (P < 0.05, Table 6).  A higher number, and 318 
proportion, of GlcN treated older mice had pregnancies characterized by at least one 319 
abnormally developing fetus, when compared to the remaining groups (P < 0.05, Table 6).  320 
Birth defects were again characterised by eye defects (8 wk – GlcN, n=2 fetuses; 16 wk – 321 
GlcN, n=3 fetuses; 16 wk + GlcN, n=7 fetuses). One fetus in the 16 wk + GlcN group 322 





Previous studies have demonstrated that in vitro exposure of the developing oocyte or 326 
preimplantation embryo to glucosamine has detrimental consequences for subsequent 327 
embryo development (Sutton-McDowall et al. 2006; Kimura et al. 2008; Pantaleon et al. 328 
2010; Schelbach et al. 2010).  Furthermore, subcutaneous administration of 40 mg 329 
(~1600-2000 mg/kg) glucosamine to pregnant mice on day 7.5 days of gestation is 330 
associated with an increased incidence of neural tube defects (Horal et al. 2004). The 331 
current study has extended these observations by demonstrating adverse effects of in 332 
vivo glucosamine administration during the periconception period on subsequent murine 333 
embryonic and fetal development.  These effects were manifested as reduced 334 
implantation rates, retarded fetal development and an increased incidence of congenital 335 
malformations, with the occurrence of these perturbations being influenced by 336 
accompanying maternal conditions.   337 
Maternal age, in particular, was shown to influence the effects of periconceptional 338 
glucosamine on reproductive outcomes.  Glucosamine treatment reduced litter size in 339 
young, 8-week old mice. The decrease in litter size was mediated in part by a reduction in 340 
mean implantation rate as well as an increase in the proportion of implantations that 341 
resorbed. In contrast, in older, adult mice (16 weeks of age), periconception glucosamine 342 
did not alter litter size, but reduced fetal weight and increased the incidence of congenital 343 
abnormalities.  Furthermore, periconceptional glucosamine increased placental weight in 344 
8-week, but not 16-week old, mice.  345 
Mechanisms involved in the generation of divergent reproductive outcomes as a result of 346 
exposure to periconception glucosamine in different aged mice are unclear and require 347 
further investigation.   In younger mice, implantation rate was decreased. Reduced litter 348 
size and the observed increase in placental weight may have contributed to maintenance 349 
of fetal size in glucosamine treated young mice.  While implantation rates were not altered 350 
in older mice, reduced fetal weight and an increased incidence of birth defects does 351 
suggest that oocyte or embryo quality has been affected by glucosamine exposure at both 352 
ages, but with differing consequences for subsequent development. The periconception 353 
glucosamine treatment protocol used in the current study may potentially affect the 354 
preovulatory, ovulated or fertilizing oocyte, the early embryo or the uterine environment 355 
and receptivity.  No significant difference in ovarian corpora lutea numbers suggests that 356 
the reduction in litter size in young mice is not due to fewer oocytes being ovulated.  Body 357 
weight is higher in adult, compared to young mice, but body composition was not 358 
assessed in the current study.  Whether changes in adiposity or metabolic indices could 359 
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have influenced the metabolism or actions of glucosamine at different ages is unclear.  360 
Body weight differences would result in a minor difference in total glucosamine dose 361 
administered on a per kg body weight basis, however, adverse effects were observed in 362 
the young mice, that would have received the lower total dose.  Age related changes in 363 
activity of the hexosamine signalling pathway have been suggested; with one study 364 
reporting an increase in hexosamine biosynthesis pathway  activity in aged rats (Einstein 365 
et al. 2008), while others report reductions in skeletal muscle activity of the GFAT enzyme 366 
and reduced levels of O-linked N-acetyl glucosamine (O-GlcNac) and O-GlcNAc 367 
transferase (OGT) in heart in mice and rats, across a similar age span to that assessed in 368 
the current study (Buse et al. 1997; Fulop et al. 2007).  Previous in vitro studies have 369 
supported a role for glucosamine induced increases in flux through the hexosamine 370 
biosynthesis pathway, and an associated increase in O-linked glycosylation in the 371 
cumulus-oocyte-complex or early embryo, in mediating the adverse effects of 372 
glucosamine (Pantaleon et al. 2010; Schelbach et al. 2010).  Further studies are required 373 
to assess the specific mechanisms through which short-term, periconceptional 374 
glucosamine administration is affecting oocyte and embryo developmental competence in 375 
vivo, including assessment of the hexosamine biosynthesis pathway and O-linked 376 
glycosylation, and to more fully characterise the interaction with maternal age.  377 
The metabolic perturbations accompanying diabetes and obesity are associated with 378 
upregulation of the hexosamine biosynthesis pathway (Robinson et al. 1995; Buse et al. 379 
1997; Considine et al. 2000; Veerababu et al. 2000, Kaneto et al. 2001; McClain 2002) 380 
and both conditions are associated with an increased incidence of adverse pregnancy 381 
outcomes, including miscarriage, congenital abnormalities and altered fetal growth (Miller 382 
et al. 1981; Combs and Kitzmiller 1991; Greene 1999; Stothard et al. 2009; Simmons, 383 
2011).  Studies have demonstrated negative effects of exposing the developing oocyte or 384 
embryo to maternal hyperglycaemia in vivo or in vitro (Diamond et al. 1989; Moley et al. 385 
1991; Wyman et al. 2008; Jungheim and Moley 2008; Wang et al. 2009; Ramin et al. 386 
2010; Wang and Moley 2010) and improved glycemic control during the pre- and early 387 
pregnancy period in women with diabetes has been associated with reduced incidence of 388 
miscarriage and risk for fetal abnormalities (Ray et al. 2001; Temple et al. 2006).  389 
Furthermore, embryos collected at the one-cell stage from diabetic mice, and transferred 390 
to normoglycemic recipients, have an increased incidence of retarded fetal growth and 391 
fetal abnormalities (Wyman et al. 2008), providing clear evidence that exposure to 392 
perturbed maternal glucose metabolism during the periconceptional period can affect 393 
subsequent fetal development.  394 
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In the current study, we therefore further assessed the effects of periconception 395 
glucosamine in overweight mice that had been maintained on a high fat diet, to assess 396 
glucosamine effects under perturbed metabolic conditions which may be associated with 397 
upregulation of the hexosamine pathway.  Increased fasting serum insulin, glucose and 398 
free fatty acids, and increased adipose tissue weight, have previously been reported 399 
following 16 weeks exposure to the same high fat diet used in the present study (Minge et 400 
al. 2008).  However, high fat fed mice in the current study did not demonstrate differences 401 
in glucose tolerance or fasting insulin, following 11 weeks dietary intervention, suggesting 402 
that longer dietary exposure may have been required to induce detectable impairments in 403 
insulin and glucose metabolism. Specific assessment of insulin sensitivity may have also 404 
been required to more fully characterise the effects. Nevertheless, fat fed mice were 405 
overweight suggesting that some degree of metabolic perturbation did occur and the 406 
observed effects of the high fat diet on fetal size support this. Litter size was not altered in 407 
high fat fed mice, however, in agreement with previous studies, feeding a high fat diet 408 
before and throughout pregnancy reduced fetal weight and length (Jungheim et al. 2010), 409 
irrespective of glucosamine treatment.  These findings extend a previous study reporting 410 
adverse effects of this diet on blastocyst development (Minge et al. 2008).   411 
Periconception glucosamine treatment reduced fetal weight in 16 week old mice fed 412 
control chow; however, no additive effects of glucosamine treatment and high fat feeding 413 
on reproductive outcomes were observed. Other studies have reported that glucosamine 414 
administration, or upregulation of the hexosamine biosynthesis pathway through 415 
overexpression of the GFAT enzyme, does not potentiate high fat feeding induced insulin 416 
resistance in rats or mice (Barrientos et al. 2010; Cooksey and McClain 2010), suggesting 417 
a potential for maximal upregulation of the pathway.  The lack of additive effects may also 418 
implicate a role for the hexosamine biosynthesis pathway in mediating the negative 419 
effects of periconception high fat diets on oocyte and embryo competence, however, 420 
specific analyses of hexosamine biosynthesis pathway activity and its downstream 421 
effectors in reproductive tissues from obese mice are required to assess this further. 422 
Animal studies have demonstrated reductions in insulin sensitivity following intravenous 423 
administration of glucosamine (Rossetti et al. 1995; Virkamaki et al. 1997; Patti et al. 424 
1999; Stampinato et al. 2003). Despite some studies suggesting similar effects in 425 
humans, systematic reviews of clinical studies have identified limited evidence for an 426 
effect of oral glucosamine on insulin sensitivity or glucose tolerance in human subjects, 427 
but acknowledge the need for further study in subjects with existing risk of impaired 428 
glucose metabolism (Anderson et al. 2005; Dostrovosky et al. 2011; Simon et al. 2011). 429 
The current study did not detect any differences in glucose tolerance in non-pregnant 430 
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mice following 5 days of intraperitoneal glucosamine administration, but insulin sensitivity 431 
was not assessed. Nevertheless, despite the lack of measurable effects of acute 432 
glucosamine administration on glucose or insulin levels, effects of glucosamine on 433 
reproductive outcomes were observed, suggesting that the effects of short-term 434 
glucosamine have occurred independent of measurable metabolic perturbations.   435 
In mice, in vivo uptake of radiolabelled glucosamine has been detected in follicular fluid, 436 
and cells of the ovarian follicle, suggesting that glucosamine is not metabolised 437 
exclusively externally to the reproductive system, and indicating the potential for tissue 438 
specific effects, distinct from peripheral metabolic effects (Fowler and Guttridge 1987; 439 
Fowler 1988; Fowler and Barrett 1989; Horal et al. 2004). Bioavailability of GlcN is 440 
dependent upon its route of administration (Aghazadeh-Habashi et al. 2002). 441 
Intraperitoneally injected GlcN has been shown to have complete bioavailability, 442 
resembling intravenous administration  (Aghazadeh-Habashi et al. 2002),  while  443 
bioavailability of orally administered glucosamine is low (Setnikar et al. 1993; Adebowale 444 
et al. 2002; Aghazadeh-Habashi et al. 2002; Persiani et al. 2005),  Intraperitoneal 445 
injection of glucosamine in the current study allowed administration of a consistent, 446 
bioavailable glucosamine dose.  However, while the dose of 20 mg/kg (0.5 mg in a 25 g 447 
mouse) used in this study resembles the commonly recommended oral dose of 1500 mg 448 
in an adult human, differences in the route of administration may result in a higher 449 
bioavailable dosage in this study. Nevertheless, in contrast to a previous study reporting 450 
adverse effects of postimplantation treatment with high doses of glucosamine (Horal et al. 451 
2004), the current study has utilised treatment within a physiologically relevant range. 452 
Periconceptional glucosamine treatment was associated with an increase in placental 453 
weight in young mice.  The effects of maternal metabolic perturbation on placental 454 
development are complex and dependent on the timing and nature of the perturbation.  455 
For example, feeding mice a diet high in fat and sugar throughout pregnancy reduces 456 
fetal and placental weight (Vaughan et al. 2012), while no effect on placental weight, but 457 
an increase in fetal weight, has been reported in high fat fed mice (Jones et al. 2009). 458 
Transient hyperglycaemia in early-mid gestation in the rat (day 10) has been reported to 459 
increase placental weight (Ericsson et al. 2007).    However, studies assessing the effects 460 
of periconceptional metabolic perturbations (eg. Wyman et al. 2008) have generally not 461 
reported on placental outcomes. Further assessment of placental structure and nutrient 462 
transport capacity would be required to determine whether increased placental weight in 463 
glucosamine treated young mice was associated with altered function.  Similarly, fetal 464 
weight was reduced, while placental size was unaffected, in mice fed high fat diets 465 
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throughout pregnancy in the current study.  Whether altered placental structure or 466 
function contributed to reduced fetal growth in fat-fed mice requires further analysis. 467 
Abnormalities observed following exposure of oocytes and preimplantation embryos to 468 
hyperglycaemia included neural tube defects, limb deformities and growth retardation 469 
(Wyman et al. 2008). Similarly, common malformations associated with diabetic 470 
pregnancies are heart, neural tube and caudal defects (Salbaum and Kappen 2011).  The 471 
defects observed in the current study did differ, with primarily ocular defects, and some 472 
incidences of fetal omphalocele. Preconception obesity has been associated with an 473 
increased risk of fetal omphalocele (Waller et al. 2007) and glucose transporter-1 deficient 474 
mice exhibit increased rates of microphthalmia, suggesting that metabolic perturbations 475 
could contribute to the abnormalities.  The strain of mice (C57Bl/6) used in this study do 476 
have an increased susceptibility to ophthalmic defects (Sulik et al. 1981; Parnell et al. 477 
2006).  However, acute alcohol exposure in early gestation increases the incidence of 478 
ocular defects in offspring of these mice, suggesting that perturbations during embryonic 479 
development can increase the risk (Sulik et al. 1981; Parnell et al. 2006).  480 
Advanced maternal age (Hansen 1986; Friede et al. 1988; Nybo Andersen et al. 2000; 481 
Miletic et al. 2002; Hsieh et al. 2010) and impaired maternal glucose metabolism 482 
(McCance 2011; Simmons 2011) are recognized as independent factors that perturb 483 
reproductive success rates. The increasing rate of pregnancy in older women (Martin et 484 
al. 2006, Chan et al. 2009) and the increasing incidence of metabolic disorders involving 485 
perturbed glucose metabolism (Dunstan et al. 2002; Colagiuri et al. 2005; Wang et al. 486 
2011), suggests that the potential for interactive effects should be considered.  Studies 487 
that have considered the effects of intercurrent illness on adverse perinatal outcomes in 488 
older women, to date, have suggested that the effects of older age are independent of 489 
any existing diabetes (Jacobsson et al. 2004; Delbaere et al. 2007).  Nevertheless the 490 
observation that reproductive outcomes were perturbed in adult mice of an age well within 491 
the reproductively fit range in combination with a metabolic perturbation that did not result 492 
in measurable differences in glucose metabolism, suggests that the potential for 493 
interaction should be considered. 494 
Conclusion 495 
Collectively these results demonstrate that in vivo, periconception glucosamine exposure 496 
in mice elicits detrimental effects upon fetal development that are dependent on maternal 497 
age.  Adverse effects of increased maternal weight, induced by high fat feeding, on fetal 498 
development were also confirmed, but these effects were not exacerbated by 499 
glucosamine treatment.  The specific effects at a cellular level that contribute to altered 500 
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reproductive outcomes associated with acute periconception glucosamine exposure 501 
require further study. Given that hyperglycemia elicits effects by stimulating divergent 502 
pathways, glucosamine may prove to be a useful tool to study the specific effects of this 503 
signalling pathway in glucose induced pathophysiologies and for further analysing 504 
associations between age and hyperglycemia. Previous studies have suggested 505 
dysregulation of the hexosamine biosynthesis pathway as a potential mechanism through 506 
which maternal hyperglycaemia elicits effects on oocyte and preimplantation embryo 507 
development (Schelbach et al. 2010; Pantaleon et al. 2010).  The current study, suggests 508 
that further studies should assess the potential role of increased activity of the 509 
hexosamine biosynthesis pathway, and associated effects such as increased O-linked 510 
glycosylation, in contributing to the in vivo effects of periconceptional maternal 511 
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Table 1. Composition of control (low fat) and high fat diet 
Ingredient Control High fat 
 g/kg 
Casein 195 195 
DL Methionine 3 3 
Sucrose 341 341 
Wheat Starch 306 154 
Cellulose 50 50 
Canola Oil 60 - 
Clarified butter (Ghee) - 210 
Cholesterol - 1.5 
Calcium carbonate 17.1 17.1 
Sodium chloride 2.6 2.6 
Potassium citrate 2.5 2.6 
Potassium dihydrogen phosphate 6.9 6.9 
Potassium sulphate 1.6 1.6 
AIN93G trace minerals 1.4 1.4 
Choline chloride (65%) 2.5 2.5 
SF00-219 vitamins 10 10 
Etoxyquin (66%) 0.04 0.04 
   
 Calculated values 
Protein (%) 19 19 
Total Fat (%) 6 21 
Fibre (%) 9.4 9.4 
Digestible Energy (MJ/kg) 16.1 19.4 
% Calculated energy from lipids 21 40 
   








Table 2. Effect of periconception GlcN treatment (20 or 400 mg/kg) on reproductive 
outcomes at day 18 gestation 






Mated (n) (%) 22/24 (82%) 19/24 (70%) 18/24 (67%) 
Pregnant (n) (%) 13/22 (59%) 14/19 (74%) 12/18 (67%) 
Implantations (n) 7.2 ± 0.2
a
 5.4 ± 0.3
b
 4.2 ± 0.6
b
 
Litter size (n) 6.0 ± 0.5a 3.1 ± 0.4b 2.5 ± 0.7b 
Resorptions (n) 1.0 ± 0.3 1.1 ± 0.2 1.6 ± 0.3 
Viable d18 fetuses 
from implantations (%) 
85.4% 70.6% 62.9% 
Resorptions from 
implantations (%) 
15.7%a 29.4%b 38.7%b 
Fetal weight (mg) 792 ± 22 741 ± 42 852 ± 46 
Fetal length (mm) 18.7 ± 0.3 17.4 ± 0.6 19.9 ± 0.8 
Placental weight (mg) 80.2 ± 1.1 87.8 ± 2.1 85.3 ± 2.9 
Implantations represents the mean number of implantation sites (sum of viable and non-
viable fetuses and resorption sites) detected per mouse at day 18 gestation.  Litter size 
represents the number of viable fetuses at day 18 gestation.  Fetal and placental data 
represent n=74 (0 mg/kg), n=38 (20 mg/kg) and n=36 (400 mg/kg). Data presented as mean 




Table 3. Effect of high fat feeding and periconception GlcN treatment (20 mg/kg) on 
reproductive outcomes at day 18 gestation 
 LF - GlcN LF + GlcN HF - GlcN HF + GlcN 
Ovulation rate 10.4 ± 0.6 9.3 ± 0.1 9.1 ± 0.2 11.2 ± 1.1 
Mated (n) (%) 28/48 (58%) 28/48 (58%) 25/48 (52%) 26/48(54%) 
Pregnant (n) (%) 12/28 (43%)a,c 20/28 (71%)b 15/25 (60%)a,b 8/26 (31%)c 
Implantations (n) 8.8 ± 0.9 9.1 ± 0.6 7.6 ± 0.8 9.0 ± 0.5 
Litter size (n) 7.0 ± 0.8 8.2 ± 0.6 7.1 ± 0.8 8.2 ± 0.6 
Viable d18 fetuses 
from implantations (%) 
86.1% 88.0% 88.9% 91.4% 
Resorptions (n) 1.2 ± 0.3 1.1 ± 0.3 0.8 ± 0.3 0.8 ± 0.2 
Resorptions from 
implantations (%) 
13.0% 12.0% 11.1% 8.6% 
Ovulation rate represent the number of corpora lutea present on the ovary at day 18 
gestation.  Litter size represents the number of viable fetuses at day 18 gestation.  Data 
presented as mean ± sem.  LF = mice maintained on a control diet, HF = mice maintained 
on a high fat diet.  Values with different superscripts are significantly different, P < 0.05. 
 
Table 4. Effect of high fat feeding and periconception GlcN treatment (20 mg/kg) on 
fetal and placental outcomes at day 18 gestation 
 LF - GlcN LF + GlcN HF - GlcN HF + GlcN 
Fetal weight (mg) 904 ± 55a 761 ± 14b 658 ± 14c 680 ± 16c 
Fetal length (mm) 18.0 ± 0.2a 18.8 ± 0.2a 17.9 ± 0.2b 17.7 ± 0.2b 
Placental weight (mg) 74.7 ± 1.4 73.1 ± 1.0 72.5 ± 1.3 73.1 ± 1.6 
Placental volume (mm2) 123 ± 6 134 ± 6 118 ± 6 117 ± 6 
Fetuses with 
abnormalities 
0a 17b 4c 3 ac 
Proportion abnormal 
from total fetuses 
0/99 (0%)a 17/161 (11%)b 4/88 (5%)a 3/74 (4%)a 
Pregnancies with 
abnormal fetus  
0a 9b 2a 2a 
Proportion pregnancies 
with abnormal fetus 
0/10 (0%)a 9/20 (45%)b 2/15 (13%)c 2/8 (25%)c 
Data presented as mean ± sem.  LF = mice maintained on a control diet, HF = mice 
maintained on a high fat diet. Data are from n=12 litters, 91 fetuses (LF - GlcN), n= 20 litters, 
151 fetuses (LF + GlcN), n= 15 litters, 103 fetuses (HF - GlcN), n=8 litters, 74 fetuses (HF + 
GlcN). Values with different superscripts are significantly different, P < 0.05. 
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Table 5. Effect of maternal age at mating and periconception GlcN treatment (20 
mg/kg) on reproductive outcomes at day 18 gestation 
 8 wk - GlcN 8 wk + GlcN 16 wk - GlcN 16 wk + GlcN 
Ovulation rate 11.4 ± 1.3 9.0 ± 2.6 12.2 ± 0.6 12.8 ± 0.7 
Mated (n) (%) 20/24 (83%) 19/24 (79%) 21/24 (88%) 19/24 (79%) 
Pregnant (n) (%) 11/20 (55%) 7/19 (37%) 9/21 (43%) 11/19 (58%) 
Implantations (n) 8.0 ± 0.3a 6.1 ± 0.8b 10.1 ± 0.5c 8.5 ± 0.4a c 
Litter size (n) 7.0 ± 0.3a 4.4 ± 0.6b 8.5 ± 0.5c 7.5 ± 0.6a c 
Viable d18 fetuses 
from implantations (%) 
86.5% 72.1% 84.6% 88.3% 
Resorptions (n) 1.3 ± 0.2 1.7 ± 0.7 1.5 ± 0.3 1.0 ± 0.3 
Resorptions from 
implantations (%) 
13.5%a 27.9%b 15.4%a 11.7%a 
Ovulation rate represent the number of corpora lutea present on the ovary at day 18 
gestation.  Litter size represents the number of viable fetuses at day 18 gestation.  Data 
presented as mean ± sem.  Mice were mated at 8 weeks (8 wk) or 16 weeks (16 wk) of age. 
Values with different superscripts are significantly different, P<0.05.  
 
Table 6. Effect of maternal age at mating and periconception GlcN treatment (20 
mg/kg) on reproductive outcomes at day 18 gestation 
 8 wk - GlcN 8 wk + GlcN 16 wk - GlcN 16 wk + GlcN 
Fetal weight (mg) 851 ± 23a 827 ± 34a 866 ± 35a 746 ± 20b 
Fetal length (mm) 19.6 ± 0.2a 19.6 ± 0.6a 19.5 ± 0.4a 18.6 ± 0.2b 
Placental weight (mg) 74.7 ± 1.6a 88.0 ± 2.5b 79.1 ± 2.1a 80.8 ± 1.6a 
Placental volume (mm2) 128 ± 0.5 138 ± 3 126 ± 4 141 ± 5 
Fetuses with 
abnormalities 
2a 0a 3a 8b 
Proportion abnormal 
from total fetuses 
2/77 (3%) 0/31 (0%) 3/77 (4%) 8/83 (10%) 
Pregnancies with 
abnormal fetus  
2a 0a 2a 5b 
Proportion pregnancies 
with abnormal fetus 
2/11 (18%)a 0/7 (0%)b 2/9 (22%)a 5/11 (45%)c 
Data presented as mean ± sem.  Mice were mated at 8 weeks (8 wk) or 16 weeks (16 wk) of 
age. Data are from n=11 litters, 77 fetuses (8 wk - GlcN), n= 7 litters, 31 fetuses (8 wk + 
GlcN), n= 9 litters, 77 fetuses (16 wk - GlcN), n= 11 litters, 83 fetuses (16 wk + GlcN). 
Values with different superscripts are significantly different, P < 0.05. 
